UroGen Pharma (URGN) Long-Term Investments (2016 - 2026)
UroGen Pharma (URGN) posted quarterly Long-Term Investments of $177000.0 for Q1 2026, down 96.08% year-on-year from $4.5 million in Q1 2025, and little changed on a QoQ basis from $177000.0 in Q4 2025.
UroGen Pharma (URGN) Long-Term Investments (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has reported Long-Term Investments for 11 consecutive years, with $177000.0 the latest figure, recorded in Q1 2026.
- Quarterly Long-Term Investments fell 96.08% year-over-year to $177000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177000.0 (down 96.08% YoY) and the FY2025 annual result came in at $177000.0, down 96.48% from the prior year.
- Long-Term Investments steadied at $177000.0 in Q1 2026 per URGN's latest filing, from $177000.0 in the prior quarter.
- Over the last five years, Long-Term Investments for URGN reached as high as $10.2 million in Q1 2023 and fell as low as $177000.0 in Q4 2025.
- A 5-year average of $3.0 million and a median of $674000.0 in 2022 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2023 — Long-Term Investments surged 2817.94% — and 2024, when it tumbled 97.45%.
- Year by year, Long-Term Investments stood at $223000.0 in 2022, then jumped by 1918.83% to $4.5 million in 2023, then rose by 11.55% to $5.0 million in 2024, then sank by 96.48% to $177000.0 in 2025, then changed by 0.0% to $177000.0 in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $177000.0, $177000.0, and $380000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | 177,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 177,000.00 |
| Dec 31, 2025 | 177,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | 4.63 Mn |
| Mar 31, 2025 | 4.51 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 4.64 Mn |
| Jun 30, 2024 | 203,000.00 |
| Mar 31, 2024 | 481,000.00 |
| Dec 31, 2023 | 4.50 Mn |
| Sep 30, 2023 | 6.51 Mn |
| Jun 30, 2023 | 7.97 Mn |
| Mar 31, 2023 | 10.17 Mn |
| Dec 31, 2022 | 223,000.00 |
| Sep 30, 2022 | 223,000.00 |
| Jun 30, 2022 | 673,000.00 |
| Mar 31, 2022 | 674,000.00 |
| Dec 31, 2021 | 675,000.00 |
| Sep 30, 2021 | 4.07 Mn |
| Jun 30, 2021 | 8.29 Mn |